REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)

6 Months Ended

Jun. 30, 2020

Concentration Risk And Geographic Information [Abstract]

Schedule of Total Revenues from External Customers and Collaborative Partners by Geographic Region

The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme, which is sold exclusively to Sanofi Genzyme (Genzyme) who markets and sells Aldurazyme world-wide. Aldurazyme revenues earned by the Company are included in the U.S. region as the transactions are with Genzyme, whose headquarters is located in the U.S. 

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Total revenues by geographic region:
United States	$	232,552	$	169,407	$	476,724	$	360,343
Europe	109,259		119,561		254,295		244,100
Latin America	37,864		46,494		97,788		80,333
Rest of world	49,810		52,301		102,747		103,732
Total revenues	$	429,485	$	387,763	$	931,554	$	788,508

Schedule of Net Product Revenues by Product

The following table disaggregates Net Product Revenues by product. 

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Net product revenues by product:
Kuvan	$	122,611	$	113,323	$	244,611	$	220,247
Vimizim	116,695		122,686		253,898		248,487
Naglazyme	81,006		98,127		195,262		185,054
Palynziq	40,630		18,836		75,262		31,108
Brineura	25,798		14,795		49,768		26,975
Firdapse	—		5,482		1,316		10,594
Total net product revenues marketed by the Company	$	386,740	$	373,249	$	820,117	$	722,465
Aldurazyme net product revenues marketed by Genzyme	32,292		5,826		$	87,958	$	51,093
Total net product revenues	$	419,032	$	379,075	$	908,075	$	773,558

Schedule of Total Net Product Revenues Based on Patient Location

The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme. 

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
United States	$	197,171	$	160,918	$	378,842	$	305,203
Europe	104,319		113,593		245,170		236,678
Latin America	37,864		46,493		97,788		80,333
Rest of world	47,386		52,245		98,317		100,251
Total net product revenues marketed by the Company	386,740		373,249		820,117		722,465
Aldurazyme net product revenues marketed by Genzyme	32,292		5,826		87,958		51,093
Total net product revenues	$	419,032	$	379,075	$	908,075	$	773,558

Schedule of Net Product Revenue Concentrations Attributed to Largest Customers

The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. 

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Customer A	16	%	13	%	14	%	12	%
Customer B	15	%	16	%	14	%	17	%
Customer C	13	%	12	%	12	%	11	%
Total	44	%	41	%	40	%	40	%